Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : anika research(anik) -- Ignore unavailable to you. Want to Upgrade?

To: Andreas Helke who wrote (140)	7/21/1998 7:58:00 PM
From: virgil vancleave	Read Replies (1) \| Respond to of 328

fda approval is just a matter of time and as you stated, sales over in europe just starting to ramp up. sales should also start improving in canada, which is more than likely why the agreement with zimmer. good things will keep happenning with this company. they are profitable which means no equity offerings for research cash. they also have nearly 3 dollars per share in cash on the books. it appears to me that the selloff from 16 to 14 was the market action. market sure took a nosedive late this afternoon. anik should hold support in the 14's and may even go to the 16's, where there is some support there also. hope this helps. good luck.